Free tool
Oncology stocks
We cover 37 companies grouped under the Oncology theme. The median market value in the group is $28.00M. Across the group, the median move over the past trading day is 0.00%. 46% of the 35 with a 200-day average trade above it. Price change over the past year runs from −66.4% to +78.0% across the middle 80 percent of the group, with a median of −9.0%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
37 of 319 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| 0J9P.L | Incyte Corporation | $129.02 | +1.10% | +29.30% | +53.49% |
| GE9.DE | Genmab A/S | 294.20 EUR | +17.26% | +9.78% | −11.12% |
| IPN.PA | Ipsen S.A. | 166.00 EUR | +1.41% | +42.98% | +40.80% |
| 0IJO.L | Exelixis, Inc. | $56.81 | +4.53% | +31.50% | +50.53% |
| 0M2N.L | Orion Oyj | 80.10 EUR | −0.50% | +28.64% | +20.48% |
| OSE.PA | OSE Immunotherapeutics SA | 3.21 EUR | −0.19% | −39.40% | −47.94% |
| 0QW5.L | Heidelberg Pharma AG | 2.46 EUR | 0.00% | −2.38% | −33.15% |
| 0J4V.L | Heron Therapeutics, Inc. | $0.31 | −3.55% | −76.14% | −78.12% |
| POLB.L | Poolbeg Pharma PLC | 8.60 GBP | +36.51% | +120.51% | +164.62% |
| 0QXX.L | Molecular Partners AG | 3.51 CHF | +2.33% | +3.54% | +17.00% |
| SAR.L | Sareum Holdings plc | 37.00 GBP | +76.19% | +117.65% | +76.19% |
| MAAT.PA | MaaT Pharma SA | 3.04 EUR | +8.96% | −45.52% | −33.91% |
| 0OCQ.L | Transgene SA | 0.81 EUR | −0.25% | −16.36% | −22.31% |
| 0RAD.L | OSE Immunotherapeutics SA | 3.19 EUR | −1.30% | −39.91% | −48.50% |
| CANTA.ST | Cantargia AB (publ) | 1.91 SEK | +3.24% | −53.64% | −27.38% |
| COIL.L | Coiled Therapeutics plc | 9.50 GBP | −9.52% | −20.83% | −26.92% |
| SVE.WA | Synthaverse S.A. | 3.06 PLN | +9.29% | −20.21% | −36.25% |
| MOC.WA | Molecure S.A. | 6.03 PLN | −2.58% | −8.08% | −22.39% |
| NNG.WA | NanoGroup S.A. | 2.38 PLN | −4.80% | −11.19% | −17.36% |
| DEX.ST | Dextech Medical AB | 10.30 SEK | −0.96% | +11.35% | +26.38% |
| ALTME.PA | TME Pharma N.V. | 0.13 EUR | +113.11% | +88.41% | +25.97% |
| ABERA.ST | Abera Bioscience AB | 8.18 SEK | −2.62% | +13.61% | +1.61% |
| B8FK.DE | Biofrontera AG | 2.53 EUR | −0.78% | −0.78% | −3.07% |
| ACTI.ST | Active Biotech AB (publ) | 5.50 SEK | +6.38% | +19.57% | −62.00% |
| CRTX.L | CRISM Therapeutics Corporation | 11.50 GBP | +21.05% | +15.00% | +9.52% |
| 0NWK.L | Valerio Therapeutics Société anonyme | 0.86 EUR | +8.09% | +418.18% | +1279.03% |
| PUR.WA | MultiQure S.A. | 3.05 PLN | +40.23% | −25.43% | −55.05% |
| ALOPM.PA | Oncodesign Precision Medicine Société anonyme | 0.32 EUR | +2.57% | −18.41% | −19.44% |
| CHOSA.ST | Chosa Oncology AB | 0.73 SEK | −14.15% | −20.00% | −9.00% |
| NFX.L | Nuformix plc | 0.16 GBP | +6.71% | −46.10% | +80.68% |
| 0GP7.L | Medivir AB (publ) | 2.03 SEK | +6.77% | +345.66% | +1.60% |
| DBP-B.ST | Double Bond Pharmaceutical International AB (publ) | 0.16 SEK | +30.42% | +16.79% | +11.79% |
| VAL.L | ValiRx plc | 0.16 GBP | +3.33% | −57.53% | −73.04% |
| 0RK9.L | Alligator Bioscience AB (publ) | 0.03 SEK | +10.16% | −90.40% | −99.13% |
| ATORX.ST | Alligator Bioscience AB (publ) | 0.03 SEK | −32.46% | −91.74% | −99.27% |
| PTP.DE | Pentixapharm Holding AG | 1.85 EUR | −5.61% | +20.13% | +5.47% |
| 0GQU.L | Active Biotech AB (publ) | 5.46 SEK | +5.61% | +7801.59% | +7801.59% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.